<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670696</url>
  </required_header>
  <id_info>
    <org_study_id>RD 305/24674</org_study_id>
    <nct_id>NCT00670696</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel</brief_title>
  <official_title>A Randomised, Controlled, Single-blinded, Cross Over Comparison Study to Compare the Efficacy of the Rapydan Medicated Plaster Versus Tetracaine Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tetracaine gel 4% is a topical anaesthetic gel commonly used in the UK that contains 40 mg of
      tetracaine base per gram. Adequate anaesthesia can usually be achieved following a 30 minute
      application time for venopuncture and a 45 minute application time for venous cannulation.
      The hypothesis is that Rapydan medicated plaster is more effective than tetracaine gel in
      preventing venous cannulation related pain when applied for the recommended treatment
      durations of 30 minutes and 45 minutes respectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tetracaine gel 4% is a topical anaesthetic gel commonly used in the UK that contains 40 mg of
      tetracaine base per gram. Adequate anaesthesia can usually be achieved following a 30 minute
      application time for venopuncture and a 45 minute application time for venous cannulation.
      The hypothesis is that Rapydan medicated plaster is more effective than tetracaine gel in
      preventing venous cannulation related pain when applied for the recommended treatment
      durations of 30 minutes and 45 minutes respectively. This study has been withdrawn and no
      additional data is available.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No longer sponsor of trial
  </why_stopped>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate superiority for Rapydan medicated plaster applied 30 minutes over tetracaine gel applied for 45 minutes in terms of reducing pain associated with venous cannulation as assessed by the subject on a 100 mm visual analog scale (VAS)</measure>
    <time_frame>VAS post venous cannulation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To demonstrate comparable tolerability between Rapydan medicated plaster and tetracaine gel</measure>
    <time_frame>Up to 14 days post exposure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapydan medicated plaster administered 30 minutes prior to cannulation on Visit 1 and tetracaine gel administered 45 minutes prior to cannulation on Visit 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tetracaine gel administered 45 prior to cannulation on Visit 1 and then Rapydan administered 30 minutes prior to cannulation on Visit 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapydan</intervention_name>
    <description>Topical anaesthetic plaster</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracaine gel</intervention_name>
    <description>Topical tetracaine gel</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects of any race, 18 yrs or older

          -  No clinically significant findings on physical exam

          -  Signed informed consent

        Exclusion Criteria:

          -  Damaged, denuded or broken skin at the designated site for application of the
             medicated plaster or gel.

          -  Know allergies to lidocaine, tetracaine or other local anaesthetics

          -  Concomitant use of prescription strength analgesics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul Dimber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EUSA Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merthyr Tydfill Industrial Estate</name>
      <address>
        <city>Merthyr</city>
        <state>Tydfill</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>May 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2008</study_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Topical anesthesia</keyword>
  <keyword>Rapydan</keyword>
  <keyword>Topical anaesthesia for venous cannulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetracaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

